Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Onco Targets Ther. 2013 Sep 24;6:1341-5. doi: 10.2147/OTT.S45705. eCollection 2013.
The aim of the study reported here was to identify whether a stem cell biomarker, Lin28, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced gastric cancer.
The study enrolled 47 patients with gastric cancer who underwent neoadjuvant chemotherapy followed by surgery between July 2004 and March 2012. Cancer tissue was biopsied by gastroscopy and Lin28 expression in the tissue was measured by immunohistochemistry. Statistical analyses were performed to identify the relationship between Lin28 expression and tumor regression grade.
Of the 47 cases, pathologic nonresponse was observed in 29 (61.7%) and pathologic response in 18 (38.3%). Receiver-operating characteristic curve analysis showed that the histoscore of Lin28 expression with 0.325 as a cutoff value could differentiate between pathologic response and nonresponse. Multivariable analysis showed that Lin28 expression was an independent predictive factor for pathologic response to neoadjuvant chemotherapy (P = 0.006).
Lin28 expression was associated with pathologic tumor response in locally advanced gastric cancer patients undergoing neoadjuvant chemotherapy. This may suggest that Lin28 can serve as a predictive biomarker for neoadjuvant chemotherapy in patients with gastric cancer.
本研究旨在探讨干细胞标志物 Lin28 是否可预测局部进展期胃癌患者新辅助化疗的病理肿瘤反应。
本研究纳入 2004 年 7 月至 2012 年 3 月间接受新辅助化疗后行手术治疗的 47 例胃癌患者。通过胃镜活检获取肿瘤组织，采用免疫组化法检测组织中 Lin28 的表达。统计学分析用于确定 Lin28 表达与肿瘤退缩分级之间的关系。
47 例患者中，29 例（61.7%）为病理无应答，18 例（38.3%）为病理应答。受试者工作特征曲线分析显示，以 0.325 为截断值的 Lin28 表达组织评分可区分病理应答和无应答。多变量分析显示，Lin28 表达是新辅助化疗病理应答的独立预测因素（P=0.006）。
Lin28 表达与接受新辅助化疗的局部进展期胃癌患者的病理肿瘤反应相关。这提示 Lin28 可作为胃癌患者新辅助化疗的预测生物标志物。
